Literature DB >> 17392432

Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase.

Catherine M Eakin1, Michael J Maccoss, Gregory L Finney, Rachel E Klevit.   

Abstract

The breast cancer suppressor protein, BRCA1, is a ubiquitin ligase expressed in a wide range of tissues. However, inheritance of a single BRCA1 mutation significantly increases a woman's lifetime chance of developing tissue-specific cancers in the breast and ovaries. Recently, studies have suggested this tissue specificity may be linked to inhibition of estrogen receptor alpha (ERalpha) transcriptional activation by BRCA1. Here, we show that ERalpha is a putative substrate for the BRCA1/BARD1 ubiquitin ligase, suggesting a possible mechanism for regulation of ERalpha activity by BRCA1. Our results show ERalpha is predominantly monoubiquitinated in a reaction that involves interactions with both BRCA1 and BARD1. The regions of BRCA1/BARD1 necessary for ERalpha ubiquitination include the RING domains and at least 241 and 170 residues of BRCA1 and BARD1, respectively. Cancer-predisposing mutations in BRCA1 are observed to abrogate ERalpha ubiquitination. The identification of ERalpha as a putative BRCA1/BARD1 ubiquitination substrate reveals a potential link between the loss of BRCA1/BARD1 ligase activity and tissue-specific carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392432      PMCID: PMC1851571          DOI: 10.1073/pnas.0610887104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation.

Authors:  R Hashizume; M Fukuda; I Maeda; H Nishikawa; D Oyake; Y Yabuki; H Ogata; T Ohta
Journal:  J Biol Chem       Date:  2001-03-06       Impact factor: 5.157

Review 2.  Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions.

Authors:  David M Lonard; Carolyn L Smith
Journal:  Steroids       Date:  2002-01       Impact factor: 2.668

3.  Autoubiquitination of the BRCA1*BARD1 RING ubiquitin ligase.

Authors:  Angus Chen; Frida E Kleiman; James L Manley; Toru Ouchi; Zhen-Qiang Pan
Journal:  J Biol Chem       Date:  2002-04-01       Impact factor: 5.157

4.  Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex.

Authors:  Peter S Brzovic; Jennifer R Keeffe; Hiroyuki Nishikawa; Keiko Miyamoto; David Fox; Mamoru Fukuda; Tomohiko Ohta; Rachel Klevit
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

Review 5.  Back to the future with ubiquitin.

Authors:  Cecile M Pickart
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

6.  BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number.

Authors:  Lea M Starita; Yuka Machida; Satish Sankaran; Joshua E Elias; Karen Griffin; Brian P Schlegel; Steven P Gygi; Jeffrey D Parvin
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

7.  BRCA1 ubiquitylation of CtIP: Just the tIP of the iceberg?

Authors:  Louise J Barber; Simon J Boulton
Journal:  DNA Repair (Amst)       Date:  2006-10-05

8.  BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II.

Authors:  Lea M Starita; Andrew A Horwitz; Michael-Christopher Keogh; Chikashi Ishioka; Jeffrey D Parvin; Natsuko Chiba
Journal:  J Biol Chem       Date:  2005-05-10       Impact factor: 5.157

Review 9.  Progesterone-dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms.

Authors:  Orla M Conneely; Biserka Mulac-Jericevic; John P Lydon
Journal:  Steroids       Date:  2003-11       Impact factor: 2.668

10.  Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.

Authors:  F Magdinier; S Ribieras; G M Lenoir; L Frappart; R Dante
Journal:  Oncogene       Date:  1998-12-17       Impact factor: 9.867

View more
  76 in total

1.  The UBXN1 protein associates with autoubiquitinated forms of the BRCA1 tumor suppressor and inhibits its enzymatic function.

Authors:  Foon Wu-Baer; Thomas Ludwig; Richard Baer
Journal:  Mol Cell Biol       Date:  2010-03-29       Impact factor: 4.272

2.  Role of the BCA2 ubiquitin E3 ligase in hormone responsive breast cancer.

Authors:  Angelika M Burger; Fathima Kona; Yutaka Amemiya; Yuguang Gao; Stephanie Bacopulos; Arun K Seth
Journal:  Open Cancer J       Date:  2010

Review 3.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

4.  Small-molecule "BRCA1-mimetics" are antagonists of estrogen receptor-α.

Authors:  Yongxian Ma; York Tomita; Anju Preet; Robert Clarke; Erikah Englund; Scott Grindrod; Shyam Nathan; Eliseu De Oliveira; Milton L Brown; Eliot M Rosen
Journal:  Mol Endocrinol       Date:  2014-12

5.  The Histone Variant MacroH2A1 Is a BRCA1 Ubiquitin Ligase Substrate.

Authors:  Beom-Jun Kim; Doug W Chan; Sung Yun Jung; Yue Chen; Jun Qin; Yi Wang
Journal:  Cell Rep       Date:  2017-05-30       Impact factor: 9.423

6.  Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells.

Authors:  Nikolaos Svoronos; Alfredo Perales-Puchalt; Michael J Allegrezza; Melanie R Rutkowski; Kyle K Payne; Amelia J Tesone; Jenny M Nguyen; Tyler J Curiel; Mark G Cadungog; Sunil Singhal; Evgeniy B Eruslanov; Paul Zhang; Julia Tchou; Rugang Zhang; Jose R Conejo-Garcia
Journal:  Cancer Discov       Date:  2016-09-30       Impact factor: 39.397

7.  AKT regulates BRCA1 stability in response to hormone signaling.

Authors:  Andrew C Nelson; Traci R Lyons; Christian D Young; Kirk C Hansen; Steven M Anderson; Jeffrey T Holt
Journal:  Mol Cell Endocrinol       Date:  2010-01-18       Impact factor: 4.102

8.  Estrogen receptor-alpha hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome.

Authors:  Nicholas B Berry; Meiyun Fan; Kenneth P Nephew
Journal:  Mol Endocrinol       Date:  2008-04-03

9.  BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation.

Authors:  S Shabbeer; D Omer; D Berneman; O Weitzman; A Alpaugh; A Pietraszkiewicz; S Metsuyanim; A Shainskaya; M Z Papa; R I Yarden
Journal:  Oncogene       Date:  2012-12-17       Impact factor: 9.867

10.  Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.

Authors:  J Wen; R Li; Y Lu; M A Shupnik
Journal:  Oncogene       Date:  2008-11-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.